Clinical Trials Logo

Carcinosarcoma clinical trials

View clinical trials related to Carcinosarcoma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06393751 Not yet recruiting - Clinical trials for Recurrent Platinum-Resistant Ovarian Carcinoma

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

Start date: June 21, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial tests the safety, best dose and effectiveness of adding tolinapant (ASTX660) to paclitaxel with or without bevacizumab in treating patients with ovarian cancer that has come back after a period of improvement (recurrent). Tolinapant may stop the growth of tumor cells by blocking proteins, such as XIAP and cIAP1, that promote the growth of tumor cells and increase resistance to chemotherapy. Paclitaxel is in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to the tumor. This may slow the growth and spread of tumor cells. Adding ASTX660 to paclitaxel with or without bevacizumab may be safe, tolerable and/or effective in treating patients with recurrent ovarian cancer.

NCT ID: NCT02964351 Not yet recruiting - Clinical trials for Prostate Carcinosarcoma

microRNA Profiles Identification in Adeno Carcinoma Prostate Cancer

Start date: December 2016
Phase: N/A
Study type: Observational

In our study, the investigators want to find correlation between circulating miRNAs associated with prostate cancer metastases to bones and to lymph nodes separately with results of 68Ga-PSMA ligand PET (positron emission computed) imaging.